Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
3,979 results
  • Antifungal medicines in the terrestrial environment: Levels in biosolids from England and Wales. [Journal Article]
    Sci Total Environ. 2023 Feb 01 [Online ahead of print]Martin I, Hart A
  • Antifungals are used widely in clinical and agricultural practice to control fungal growth, either treating or preventing infection. There are reports of increasing prevalence of resistance to antifungals in human pathogens and concern that their use in agriculture is driving clinical resistance in patients. While crop protection products are the most obvious source in agriculture, a further sour…
  • Carbon Dioxide Potentiates Flucytosine Susceptibility in Cryptococcus neoformans. [Journal Article]
    Microbiol Spectr. 2023 Jan 31 [Online ahead of print]Jezewski AJ, Ristow LC, Krysan DJ
  • Cryptococcal meningoencephalitis remains a global health threat with limited treatment options. Currently, the most effective treatment regimens are based on a combination therapy of flucytosine with either amphotericin B or fluconazole. Slow but steady progress is being made toward universal access to flucytosine-based therapies. The broadening access to flucytosine combination therapies will be…
  • Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis. [Review]
    Future Microbiol. 2023 Jan 23 [Online ahead of print]Alves V, Araújo GR, Frases S
  • Cryptococcosis is an opportunistic mycosis that mainly affects immunosuppressed patients. The treatment is a combination of three antifungal agents: amphotericin B, 5-flucytosine and fluconazole. However, these drugs have many disadvantages, such as high nephrotoxicity, marketing bans in some countries and fungal resistance. One of the solutions to find possible new drugs is pharmacological repos…
  • Factors Influencing the Nitrogen-Source Dependent Flucytosine Resistance in Cryptococcus Species. [Journal Article]
    mBio. 2023 Jan 19 [Online ahead of print]Yang DH, Khanal Lamichhane A, … Chang YC
  • Flucytosine (5-FC) is an antifungal agent commonly used for treatment of cryptococcosis and several other systemic mycoses. In fungi, cytosine permease and cytosine deaminase are known major players in flucytosine resistance by regulating uptake and deamination of 5-FC, respectively. Cryptococcus species have three paralogs each of cytosine permease (FCY2, FCY3, and FCY4) and cytosine deaminase (…
  • A survey to describe common practices on antifungal monitoring among Spanish clinicians. [Journal Article]
    Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jan; 41(1):18-23.Gómez-López A, Martín-Gómez MT, … partners of the Study Group of Fungal Infections (GEMICOMED) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)
  • CONCLUSIONS: The survey reveals common practices and attitudes towards antifungal monitoring, sometimes not performed as per best recommendations, offering an opportunity for education and research. Appropriate use of therapeutic drug monitoring may be an objective of antifungal stewardship programmes.
  • Evaluation of experimental, computational, molecular docking and dynamic simulation of flucytosine. [Journal Article]
    J Biomol Struct Dyn. 2022 Dec 23 [Online ahead of print]Agarwal N, Fatima A, … Javed S
  • Flucytosine (5-fluorocytosine), a fluorine derivative of pyrimidine, has been studied both experimentally and quantum chemically. To obtain the optimized structure, vibrational frequencies and other various parameters, the B3LYP method with a 6-311++G(d,p) basis set was used. Atom-in-molecule theory was used to calculate the binding energies, ellipticity and isosurface projection by electron loca…
  • StatPearls: Flucytosine [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)PaddaInderbir S.ISUniversity of WashingtonParmarMayurMNova Southeastern UniversityBOOK
  • Flucytosine is a medication used in the management and treatment of systemic and severe candida and cryptococcus infections. It is in the antimetabolite, antifungal class of drugs. This activity outlines the indications, action, and contraindications for flucytosine as a valuable agent in treating and managing severe fungal infections. This activity will highlight the mechanism of action, adverse…
  • Antifungal chemotherapies and immunotherapies for the future. [Review]
    Parasite Immunol. 2023 Feb; 45(2):e12960.Armstrong-James D
  • Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response. Whilst current antifungal therapies are limited to the orally available triazoles, intravenous echonoc…
  • Pulmonary Cryptococcosis. [Review]
    J Fungi (Basel). 2022 Oct 31; 8(11)Howard-Jones AR, Sparks R, … Chen SC
  • Pulmonary cryptococcosis describes an invasive lung mycosis caused by Cryptococcus neoformans or Cryptococcus gattii complex. It is often a high-consequence disease in both immunocompromised and immunocompetent populations, and may be misdiagnosed as pulmonary malignancy, leading to a delay in therapy. Epidemiology follows that of cryptococcal meningoencephalitis, with C. gattii infection more co…
  • Antifungal Combinations against Candida Species: From Bench to Bedside. [Review]
    J Fungi (Basel). 2022 Oct 13; 8(10)Fioriti S, Brescini L, … Barchiesi F
  • Candida spp. is the major causative agent of fungal infections in hospitalized patients and the fourth most common cause of nosocomial bloodstream infection (BSI). The availability of standardized methods for testing the in vitro activity of antifungals along with the expanding of antifungal armamentarium, the rising of drug-resistance and the persistence of a high mortality rate in systemic cand…
  • Cryptococcus neoformans Presenting as a Lung Mass in an Immunocompromised Patient. [Case Reports]
    Am J Case Rep. 2022 Oct 02; 23:e936968.Qurashi S, Saleem T, … Holleran L
  • BACKGROUND Pulmonary cryptococcosis is an uncommon infection mainly affecting immunocompromised individuals. Presentation of cryptococcal disease ranges from asymptomatic pulmonary colonization to severe pneumonia. It can progress to acute respiratory failure and life-threatening meningoencephalitis. CASE REPORT A 55-year-old woman with a history of a kidney transplant, on immunosuppressive thera…
New Search Next